keyword
MENU ▼
Read by QxMD icon Read
search

Car NK

keyword
https://www.readbyqxmd.com/read/27887866/continuously-expanding-car-nk-92-cells-display-selective-cytotoxicity-against-b-cell-leukemia-and-lymphoma
#1
Sarah Oelsner, Miriam E Friede, Congcong Zhang, Juliane Wagner, Susanne Badura, Peter Bader, Evelyn Ullrich, Oliver G Ottmann, Hans Klingemann, Torsten Tonn, Winfried S Wels
BACKGROUND AIMS: Natural killer (NK) cells can rapidly respond to transformed and stressed cells and represent an important effector cell type for adoptive immunotherapy. In addition to donor-derived primary NK cells, continuously expanding cytotoxic cell lines such as NK-92 are being developed for clinical applications. METHODS: To enhance their therapeutic utility for the treatment of B-cell malignancies, we engineered NK-92 cells by lentiviral gene transfer to express chimeric antigen receptors (CARs) that target CD19 and contain human CD3ζ (CAR 63...
November 22, 2016: Cytotherapy
https://www.readbyqxmd.com/read/27765614/genetically-re-engineered-k562%C3%A2-cells-significantly-expand-and-functionally-activate-cord-blood-natural-killer-cells-potential-for-adoptive-cellular-immunotherapy
#2
Janet Ayello, Jessica Hochberg, Allyson Flower, Yaya Chu, Laxmi V Baxi, William Quish, Carmella van de Ven, Mitchell S Cairo
Natural killer (NK) cells play a significant role in reducing relapse in patients with hematological malignancies after allogeneic stem cell transplantation, but NK cell number and naturally occurring inhibitory signals limit their capability. Interleukin-15 (IL-15) and 4-1BBL are important modulators of NK expansion and functional activation. To overcome these limitations, cord blood mononuclear cells (CB MNCs) were ex vivo expanded for 7 days with genetically modified K562-mbIL15-41BBL (MODK562) or wild-type K562 (WTK562)...
October 17, 2016: Experimental Hematology
https://www.readbyqxmd.com/read/27655849/cytokine-induced-memory-like-natural-killer-cells-exhibit-enhanced-responses-against-myeloid-leukemia
#3
Rizwan Romee, Maximillian Rosario, Melissa M Berrien-Elliott, Julia A Wagner, Brea A Jewell, Timothy Schappe, Jeffrey W Leong, Sara Abdel-Latif, Stephanie E Schneider, Sarah Willey, Carly C Neal, Liyang Yu, Stephen T Oh, Yi-Shan Lee, Arend Mulder, Frans Claas, Megan A Cooper, Todd A Fehniger
Natural killer (NK) cells are an emerging cellular immunotherapy for patients with acute myeloid leukemia (AML); however, the best approach to maximize NK cell antileukemia potential is unclear. Cytokine-induced memory-like NK cells differentiate after a brief preactivation with interleukin-12 (IL-12), IL-15, and IL-18 and exhibit enhanced responses to cytokine or activating receptor restimulation for weeks to months after preactivation. We hypothesized that memory-like NK cells exhibit enhanced antileukemia functionality...
September 21, 2016: Science Translational Medicine
https://www.readbyqxmd.com/read/27653295/report-meeting-21st-nantes-actualit%C3%A3-s-transplantation-nat-when-stem-cells-meet-immunology
#4
Ignacio Anegon, Tuan Huy Nguyen
When Stem Cells Meet Immunology" has been the topic of the 21st annual "Nantes Actualités en Transplantation" (NAT) meeting (June 9-10, 2016, Nantes, France). This meeting brought together pioneers and leading experts in the fields of stem cells, biomaterials and immunoregulation. Presentations covered multipotent (mesenchymal and hematopoietic) and pluripotent (embryonic and induced) stem cells (PSC) for regenerative medicine of incurable diseases (liver, retina and inflammatory diseases, cancer), immunotherapy and blood transfusions...
September 21, 2016: Transplantation
https://www.readbyqxmd.com/read/27530534/interactions-between-natural-killer-cells-and-dendritic-cells-favour-t-helper1-type-responses-to-bcg-in-calves
#5
Carly A Hamilton, Suman Mahan, Gary Entrican, Jayne C Hope
Vaccination of neonatal calves with BCG induces a significant level of protection from infection with Mycobacterium bovis, the causative agent of bovine tuberculosis. Since neonatal vaccination of humans with BCG induces activation of NK cells, and young calves have high circulating numbers of these cells, we hypothesised that NK cells are important in the protective response to BCG. Furthermore, since NK cells play a role in shaping adaptive immune responses through interactions with DCs, we investigated the interactions between NK cells and DCs in the context of BCG...
2016: Veterinary Research
https://www.readbyqxmd.com/read/27496866/cd137-stimulation-enhances-cetuximab-induced-natural-killer-nk-dendritic-cell-dc-priming-of-anti-tumor-t-cell-immunity-in-head-and-neck-cancer-patients
#6
Raghvendra M Srivastava, Sumita Trivedi, Fernando Concha-Benavente, Sandra P Gibson, Carly Reeder, Soldano Ferrone, Robert L Ferris
PURPOSE: Cetuximab, an EGFR-specific antibody (mAb), modestly improves clinical outcome in head and neck cancer (HNC) patients. Cetuximab mediates natural killer (NK) cell:dendritic cell (DC) cross-talk by cross-linking FcγRIIIa, which is important for inducing anti-tumor cellular immunity. Cetuximab activated NK cells upregulate the costimulatory receptor CD137 (4-1BB) which, when triggered by agonistic mAb urelumab, might enhance NK cell functions, to promote T cell based immunity...
August 5, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27494836/novel-anti-cd3-chimeric-antigen-receptor-targeting-of-aggressive-t-cell-malignancies
#7
Kevin H Chen, Masayuki Wada, Amelia E Firor, Kevin G Pinz, Alexander Jares, Hua Liu, Huda Salman, Marc Golightly, Fengshuo Lan, Xun Jiang, Yupo Ma
Peripheral T-cell lymphomas (PTCLS) comprise a diverse group of difficult to treat, very aggressive non-Hodgkin's lymphomas (NHLS) with poor prognoses and dismal patient outlook. Despite the fact that PTCLs comprise the majority of T-cell malignancies, the standard of care is poorly established. Chimeric antigen receptor (CAR) immunotherapy has shown in B-cell malignancies to be an effective curative option and this extends promise into treating T-cell malignancies. Because PTCLS frequently develop from mature T-cells, CD3 is similarly strongly and uniformly expressed in many PTCL malignancies, with expression specific to the hematological compartment thus making it an attractive target for CAR design...
August 2, 2016: Oncotarget
https://www.readbyqxmd.com/read/27322989/trikes-and-bikes-join-cars-on-the-cancer-immunotherapy-highway
#8
Szun Szun Tay, Hernan Carol, Maté Biro
Unprecedented clinical success has recently been achieved in cancer immunotherapy using cytotoxic T cells armed with activating tumor-specific Chimeric Antigen Receptors (CARs). Natural killer (NK) cells, potent cytotoxic effectors, also hold potential to be effectively harnessed for immunotherapy. The anti-tumor efficacy of NK cell therapies has been limited by a lack of antigen specificity and the poor persistence of NK cells in vivo. To address these limitations, Vallera and colleagues developed novel Trispecific Killer cell Engagers (TriKEs), reported in the Feb...
November 2016: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/27253354/chimeric-antigen-receptor-engineered-cytokine-induced-killer-cells-overcome-treatment-resistance-of-pre-b-cell-acute-lymphoblastic-leukemia-and-enhance-survival
#9
Sarah Oelsner, Juliane Wagner, Miriam E Friede, Verena Pfirrmann, Sabrina Genßler, Eva Rettinger, Christian J Buchholz, Heike Pfeifer, Ralf Schubert, Oliver G Ottmann, Evelyn Ullrich, Peter Bader, Winfried S Wels
Pre-emptive cancer immunotherapy by donor lymphocyte infusion (DLI) using cytokine-induced killer (CIK) cells may be beneficial to prevent relapse with a reduced risk of causing graft-versus-host-disease. CIK cells are a heterogeneous effector cell population including T cells (CD3(+) CD56(-) ), natural killer (NK) cells (CD3(-) CD56(+) ) and natural killer T (T-NK) cells (CD3(+) CD56(+) ) that exhibit non-major histocompatibility complex (MHC)-restricted cytotoxicity and are generated by ex vivo expansion of peripheral blood mononuclear cells in the presence of interferon (IFN)-γ, anti-CD3 antibody, interleukin-2 (IL-2) and interleukin-15 (IL-15)...
October 15, 2016: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/27226093/human-lymphoid-tissues-harbor-a-distinct-cd69-cxcr6-nk-cell-population
#10
Gertjan Lugthart, Janine E Melsen, Carly Vervat, Monique M van Ostaijen-Ten Dam, Willem E Corver, Dave L Roelen, Jeroen van Bergen, Maarten J D van Tol, Arjan C Lankester, Marco W Schilham
Knowledge of human NK cells is based primarily on conventional CD56(bright) and CD56(dim) NK cells from blood. However, most cellular immune interactions occur in lymphoid organs. Based on the coexpression of CD69 and CXCR6, we identified a third major NK cell subset in lymphoid tissues. This population represents 30-60% of NK cells in marrow, spleen, and lymph node but is absent from blood. CD69(+)CXCR6(+) lymphoid tissue NK cells have an intermediate expression of CD56 and high expression of NKp46 and ICAM-1...
July 1, 2016: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/27207791/exploitation-of-natural-killer-cells-for-the-treatment-of-acute-leukemia
#11
REVIEW
Rupert Handgretinger, Peter Lang, Maya C André
Natural killer (NK) cells play an important role in surveillance and elimination of malignant cells. Their spontaneous cytotoxicity was first demonstrated in vitro against leukemia cell lines, and NK cells might play a crucial role in the therapy of leukemia. NK cell activity is controlled by an array of germ line-encoded activating and inhibitory receptors, as well as modulating coreceptors. This biologic feature can be exploited in allogeneic cell therapy, and the recognition of "missing-self" on target cells is crucial for promoting NK cell-mediated graft-versus-leukemia effects...
June 30, 2016: Blood
https://www.readbyqxmd.com/read/27177679/generation-of-bikes-and-trikes-to-improve-nk-cell-mediated-targeting-of-tumor-cells
#12
Martin Felices, Todd R Lenvik, Zachary B Davis, Jeffrey S Miller, Daniel A Vallera
Cancer immunotherapies have gained significant momentum over the past decade, particularly with the advent of checkpoint inhibitors and CAR T-cells. While the latter personalized targeted immunotherapy has revolutionized the field, a need for off-the-shelf therapies remains. The ability of NK cells to quickly lyse antibody-coated tumors and potently secrete cytokines without prior priming has made NK cells ideal candidates for antigen-specific immunotherapy. NK cells have been targeted to tumors through two main strategies: mono-specific antibodies and bi/tri-specific antibodies...
2016: Methods in Molecular Biology
https://www.readbyqxmd.com/read/27177669/modification-of-expanded-nk-cells-with-chimeric-antigen-receptor-mrna-for-adoptive-cellular-therapy
#13
Yaya Chu, Allyson Flower, Mitchell S Cairo
NK cells are bone marrow-derived cytotoxic lymphocytes that play a major role in the rejection of tumors and cells infected by viruses. The regulation of NK activation vs inhibition is regulated by the expression of a variety of NK receptors (NKRs) and specific NKRs' ligands expressed on their targets. However, factors limiting NK therapy include small numbers of active NK cells in unexpanded peripheral blood and lack of specific tumor targeting. Chimeric antigen receptors (CAR) usually include a single-chain Fv variable fragment from a monoclonal antibody, a transmembrane hinge region, and a signaling domain such as CD28, CD3-zeta, 4-1BB (CD137), or 2B4 (CD244) endodimers...
2016: Methods in Molecular Biology
https://www.readbyqxmd.com/read/27153556/a-role-for-multiple-chimeric-antigen-receptor-expressing-leukocytes-in-antigen-specific-responses-to-cancer
#14
Carmen S M Yong, Liza B John, Christel Devaud, Miles H Prince, Ricky W Johnstone, Joseph A Trapani, Phillip K Darcy, Michael H Kershaw
While adoptive immunotherapy using chimeric antigen receptor (CAR)-modified T cells can induce remission of some tumors, the role of other CAR-modified leukocytes is not well characterized. In this study, we characterize the function of leukocytes including natural killer (NK) cells, macrophages and CAR T cells from transgenic mice expressing a CAR under the control of the pan-hematopoietic promoter, vav, and determine the ability of these mice to respond to ERB expressing tumors. We demonstrate the anti-tumor functions of leukocytes, including antigen specific cytotoxicity and cytokine secretion...
June 7, 2016: Oncotarget
https://www.readbyqxmd.com/read/27145284/chimeric-antigen-receptor-t-cells-secreting-anti-pd-l1-antibodies-more-effectively-regress-renal-cell-carcinoma-in-a-humanized-mouse-model
#15
Eloah Rabello Suarez, De Kuan Chang, Jiusong Sun, Jianhua Sui, Gordon J Freeman, Sabina Signoretti, Quan Zhu, Wayne A Marasco
Advances in the treatment of metastatic clear cell renal cell carcinoma (ccRCC) have led to improved progression-free survival of many patients; however the therapies are toxic, rarely achieve durable long-term complete responses and are not curative. Herein we used a single bicistronic lentiviral vector to develop a new combination immunotherapy that consists of human anti-carbonic anhydrase IX (CAIX)-targeted chimeric antigen receptor (CAR) T cells engineered to secrete human anti-programmed death ligand 1 (PD-L1) antibodies at the tumor site...
June 7, 2016: Oncotarget
https://www.readbyqxmd.com/read/27141401/dual-targeting-of-glioblastoma-with-chimeric-antigen-receptor-engineered-natural-killer-cells-overcomes-heterogeneity-of-target-antigen-expression-and-enhances-antitumor-activity-and-survival
#16
Sabrina Genßler, Michael C Burger, Congcong Zhang, Sarah Oelsner, Iris Mildenberger, Marlies Wagner, Joachim P Steinbach, Winfried S Wels
Epidermal growth factor receptor (EGFR) and its mutant form EGFRvIII are overexpressed in a large proportion of glioblastomas (GBM). Immunotherapy with an EGFRvIII-specific vaccine has shown efficacy against GBM in clinical studies. However, immune escape by antigen-loss variants and lack of control of EGFR wild-type positive clones limit the usefulness of this approach. Chimeric antigen receptor (CAR)-engineered natural killer (NK) cells may represent an alternative immunotherapeutic strategy. For targeting to GBM, we generated variants of the clinically applicable human NK cell line NK-92 that express CARs carrying a composite CD28-CD3ζ domain for signaling, and scFv antibody fragments for cell binding either recognizing EGFR, EGFRvIII, or an epitope common to both antigens...
April 2016: Oncoimmunology
https://www.readbyqxmd.com/read/27141397/advances-in-clinical-nk-cell-studies-donor-selection-manufacturing-and-quality-control
#17
U Koehl, C Kalberer, J Spanholtz, D A Lee, J S Miller, S Cooley, M Lowdell, L Uharek, H Klingemann, A Curti, W Leung, E Alici
Natural killer (NK) cells are increasingly used in clinical studies in order to treat patients with various malignancies. The following review summarizes platform lectures and 2013-2015 consortium meetings on manufacturing and clinical use of NK cells in Europe and United States. A broad overview of recent pre-clinical and clinical results in NK cell therapies is provided based on unstimulated, cytokine-activated, as well as genetically engineered NK cells using chimeric antigen receptors (CAR). Differences in donor selection, manufacturing and quality control of NK cells for cancer immunotherapies are described and basic recommendations are outlined for harmonization in future NK cell studies...
April 2016: Oncoimmunology
https://www.readbyqxmd.com/read/27050072/a-combinational-therapy-of-egfr-car-nk-cells-and-oncolytic-herpes-simplex-virus-1-for-breast-cancer-brain-metastases
#18
Xilin Chen, Jianfeng Han, Jianhong Chu, Lingling Zhang, Jianying Zhang, Charlie Chen, Luxi Chen, Youwei Wang, Hongwei Wang, Long Yi, J Bradley Elder, Qi-En Wang, Xiaoming He, Balveen Kaur, E Antonio Chiocca, Jianhua Yu
Breast cancer brain metastases (BCBMs) are common in patients with metastatic breast cancer and indicate a poor prognosis. These tumors are especially resistant to currently available treatments due to multiple factors. However, the combination of chimeric antigen receptor (CAR)-modified immune cells and oncolytic herpes simplex virus (oHSV) has not yet been explored in this context. In this study, NK-92 cells and primary NK cells were engineered to express the second generation of EGFR-CAR. The efficacies of anti-BCBMs of EGFR-CAR NK cells, oHSV-1, and their combination were tested in vitro and in a breast cancer intracranial mouse model...
May 10, 2016: Oncotarget
https://www.readbyqxmd.com/read/27008316/cd19-car-engineered-nk-92-cells-are-sufficient-to-overcome-nk-cell-resistance-in-b-cell-malignancies
#19
Annette Romanski, Christoph Uherek, Gesine Bug, Erhard Seifried, Hans Klingemann, Winfried S Wels, Oliver G Ottmann, Torsten Tonn
Many B-cell acute and chronic leukaemias tend to be resistant to killing by natural killer (NK) cells. The introduction of chimeric antigen receptors (CAR) into T cells or NK cells could potentially overcome this resistance. Here, we extend our previous observations on the resistance of malignant lymphoblasts to NK-92 cells, a continuously growing NK cell line, showing that anti-CD19-CAR (αCD19-CAR) engineered NK-92 cells can regain significant cytotoxicity against CD19 positive leukaemic cell lines and primary leukaemia cells that are resistant to cytolytic activity of parental NK-92 cells...
July 2016: Journal of Cellular and Molecular Medicine
https://www.readbyqxmd.com/read/26970434/web-based-collaborative-care-intervention-to-manage-cancer-related-symptoms-in-the-palliative-care-setting
#20
RANDOMIZED CONTROLLED TRIAL
Jennifer L Steel, David A Geller, Kevin H Kim, Lisa H Butterfield, Michael Spring, Jonathan Grady, Weiing Sun, Wallis Marsh, Michael Antoni, Mary Amanda Dew, Vicki Helgeson, Richard Schulz, Allan Tsung
BACKGROUND: The aim of this study was to examine the efficacy of a collaborative care intervention in reducing depression, pain, and fatigue and improve quality of life. METHODS: A total of 261 patients with advanced cancer and 179 family caregivers were randomized to a web-based collaborative care intervention or enhanced usual care. The intervention included the following: 1) a web site with written and audiovisual self-management strategies, a bulletin board, and other resources; 2) visits with a care coordinator during a physician's appointment every 2 months; and 3) telephone follow-up every 2 weeks...
April 15, 2016: Cancer
keyword
keyword
120464
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"